FDA批准治疗慢阻肺新药物Striverdi Respimat

发布时间：2018-02-21 03:48

  本文关键词： 药效持续时间 慢性阻塞性肺病 气流阻塞 慢性支气管炎 FDA 呼吸困难 吸入气雾剂 药品审评 致死病因 激动剂 　出处：《中国药学杂志》2014年18期 　论文类型：期刊论文

【摘要】：正近日,FDA批准Striverdi Respimat(olodaterol)吸入气雾剂用于治疗慢性阻塞性肺病(COPD),包括出现气流阻塞的慢性支气管炎和/或肺气肿。Striverdi Respimat药效持续时间较长,每日给药一次。COPD是一种能够引起呼吸困难的严重肺部疾病,会随时间推移而恶化。其症状包括气喘、咳嗽、胸闷和气短。吸烟是引
[Abstract]:The FDA has recently approved the use of Striverdi Respimatatine olodaterol) inhaled aerosols for the treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and / or emphysema with chronic bronchitis and / or emphysema for a longer period of time. Once a day. COPD is a severe lung disease that can cause dyspnea, which can worsen over time. Symptoms include asthma, cough, chest tightness and shortness of breath.
【分类号】：R563.9
，

本文编号：1520907